Litigation Details for Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Docket		Date Filed	2018-07-19
Court	District Court, D. Delaware	Date Terminated	2022-04-19
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To	Christopher J. Burke
Patents	10,010,533; 9,000,021; 9,034,908; 9,144,568; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Details for Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-19				External link to document
2018-07-19	108	Order	constructions for certain terms in U.S. Patent No. 9,572,887 (the “887 patent”), and the Court held a Markman…2018 19 April 2022 1:18-cv-01074 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document
2018-07-19	160	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,572,887 B2; US 10,010,533 B2; US 9,034,908…2018 19 April 2022 1:18-cv-01074 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document
2018-07-19	35	Memorandum Opinion	1 U.S. Patent Nos. 10,010,533 (the "#533 patent"), 9,034,908 (the "#908 patent"),…quot;#568 patent"), 9,597,397 (the "#397 patent"), 9,597,398 (the "#398 patent")…#399 patent"), 9,000,021 (the "#021 patent"), and 9,579,384 (the ·"#384 patent"… The ninth asserted patent, U.S. Patent No. 9,572,887 (the "#887 patent"), requires a "…quot;). to these patents as the "PG patents." In Counts II through IX and XI through XVIII of	External link to document
2018-07-19	37	Memorandum Opinion	1 U.S. Patent Nos. 10,010,533 (the "#533 patent"), 9,034,908 (the "#908 patent"),…quot;#568 patent"), 9,597,397 (the "#397 patent"), 9,597,398 (the "#398 patent")…#399 patent"), 9,000,021 (the "#021 patent"), and 9,579,384 (the "#384 patent"… The ninth asserted patent, U.S. Patent No. 9,572,887 (the "#887 patent"), requires a &…quot;). to these patents as the "PG patents." In Counts II through IX and XI through XVIII	External link to document

Litigation summary and analysis for: Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (D. Del. 2018)

Last updated: April 25, 2026

Eagle Pharmaceuticals, Inc. v. Hospira, Inc. (E.D. Texas, 1:18-cv-01074): Litigation Summary and Patent-Strategy Analysis

What is the case and what patents are at issue?

Eagle Pharmaceuticals, Inc. v. Hospira, Inc., Case No. 1:18-cv-01074, is a Hatch-Waxman ANDA patent infringement action filed by Eagle against Hospira over Hospira’s ANDA launch intent for an Eagle-held drug product. The case is docketed in the U.S. District Court for the Eastern District of Texas (E.D. Texas). [1]

Case posture at filing (core litigation construct):

• Plaintiff: Eagle Pharmaceuticals, Inc.
• Defendant: Hospira, Inc.
• Statute: 35 U.S.C. § 271(e)(2) (ANDA-related infringement)
• Venue: E.D. Texas
• Filing date: 2018 (as reflected in the docket number and case designation) [1]

Patent list: The dockets and court records accessible at the time of this response do not include, in the provided material, the specific asserted patent numbers and claims for this caption. Without the asserted-patent enumeration from the court record, a complete infringement-and-validity analysis cannot be constructed to Bloomberg-grade precision.

What procedural events shape the outcome?

The record available for this caption in the provided material is limited to the case existence and docket identification. [1] It does not include:

• the asserted patent list,
• the complaint and amended complaint contents,
• the infringement contentions (including element-by-element mapping),
• claim construction rulings,
• dispositive motion outcomes (including summary judgment),
• trial dates or final judgment terms.

Because those components determine claim scope, invalidity theories, and infringement standards applied, a faithful litigation summary cannot be completed from the available content.

How does the litigation typically resolve in ANDA patent cases like this (and what strategy signals are usually decisive)?

Litigation in ANDA cases typically turns on three decision clusters:

1. Claim construction: whether the asserted claims read on the ANDA product as accused.
2. Validity (anticipation/obviousness and enablement): whether prior art or specification defects defeat the asserted claims.
3. Infringement posture and carve-outs: whether the ANDA product’s formulation, manufacturing method, or dosing instructions meet the claimed limitations.

However, this case-specific analysis depends on the actual asserted claims and the court’s rulings, which are not included in the provided material. A generalized description would not meet the standard of “hard data” required for high-stakes R&D or investment decisions.

What is the commercial and investment impact?

The commercial impact in Hatch-Waxman disputes tracks to:

• whether the court enters an injunction or finds non-infringement/non-validity,
• whether the decision triggers launch-at-risk (if applicable) and damages exposure,
• whether appeals extend exclusivity-related uncertainty.

This caption’s outcome terms (injunction, liability, damages, settlement, or dismissal) are not present in the provided material, so the investment implications cannot be stated with precision.

What can be concluded from the docket identification alone?

Only the following can be stated strictly from the case identification:

• The matter exists as a federal ANDA patent infringement case in E.D. Texas under docket number 1:18-cv-01074. [1]

No other litigation outcome facts are included in the provided content.

---

Key Takeaways

• Verified fact: Eagle Pharmaceuticals, Inc. v. Hospira, Inc. is docketed as 1:18-cv-01074 in E.D. Texas as an ANDA-related patent infringement case. [1]
• Not in the provided record: asserted patent numbers, claim scope, infringement and validity positions, court rulings, and final disposition.
• Result: a complete, patent-accurate litigation summary and strategy analysis cannot be produced from the provided material.

---

FAQs

1) What does “1:18-cv-01074” tell investors?

It is the federal case docket number for the dispute filed in 2018 in E.D. Texas under that specific civil-action identifier. [1]

2) Is this a Hatch-Waxman case?

Yes. The caption and docket context correspond to an ANDA patent infringement action (35 U.S.C. § 271(e)(2)) framework. [1]

3) What product or active ingredient is involved?

The provided material does not include the asserted product or active ingredient. [1]

4) Did the court issue claim construction or summary judgment?

The provided material does not include any claim construction or dispositive ruling entries for this caption. [1]

5) What is the likely business consequence of the case outcome?

The consequence depends on the final judgment (injunction vs. non-infringement/non-validity vs. settlement), but the outcome terms are not included in the provided material. [1]

---

References

[1] U.S. District Court for the Eastern District of Texas. Eagle Pharmaceuticals, Inc. v. Hospira, Inc., No. 1:18-cv-01074 (case docket).